We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App





New COVID-19 Immunity Study Finds Majority of Coronavirus-Infected People Retain Antibodies for Over Six Months

By HospiMedica International staff writers
Posted on 22 Dec 2020
Print article
Illustration
Illustration
A new COVID-19 immunity study has found that a very large share of people infected with coronavirus in the spring still had detectable antibodies six months later.

The study by the Finnish Institute for Health and Welfare (THL; Helsinki, Finland) aimed to find out how long the antibodies last in SARS CoV2 virus infected persons, and thus also to assess the duration of possible protection. A previous study by THL and the City of Helsinki had found that nearly all those infected with coronavirus (63/64) formed antibodies, which also remained for a period of four months in most of the participants.

The follow-up study for the serological population study of the coronavirus epidemic began in October. People aged 18 or over, who had a coronavirus infection confirmed by PCR-testing in the spring at least six months prior, were invited to take part in the study. The first blood samples were taken in early November. To date, 1,164 subjects from five different hospital districts have participated in the study. A microneutralization test developed at THL was utilized in the antibody study. The microneutralization test measures antibodies that neutralize the virus. Thus far, these antibodies have been found in 792/867 subjects (91%) in the follow-up study. The THL study found neutralizing antibodies in all 129 COVID-19 patients who had been hospitalized.

Other recent studies have also shown that neutralizing antibodies persist in a large proportion of those infected, despite a decrease in total antibodies in the months following infection. Coronaviruses that cause severe infections, such as SARS and MERS, can produce antibodies that persist for several years. The neutralizing antibodies formed in infected persons are likely to provide protection against symptoms or severe symptoms of a new infection, as evidenced by animal experiments. However, it is not yet known which amount of antibodies is sufficient to protect a person from an infection or how long the protection will last.

"The fact that antibodies persist in such a large proportion of those infected for a long time is a promising finding, and, in particular, the persistence of neutralizing antibodies can mean longer-term protection from new infection," said THL's Research Manager Merit Melin.

"Our observation that neutralizing antibodies persist in most people for more than six months after infection also increases optimism about the long-term protection provided by vaccines," added THL's Research Manager Arto Palmu.

Related Links:
Finnish Institute for Health and Welfare (THL)

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Electric Bariatric Patient Lifter
SVBL 205

Print article

Channels

Surgical Techniques

view channel
Image: LUMISIGHT and Lumicell DVS offer 84% diagnostic accuracy in detecting residual cancer (Photo courtesy of Lumicell)

Cutting-Edge Imaging Platform Detects Residual Breast Cancer Missed During Lumpectomy Surgery

Breast cancer is becoming increasingly common, with statistics indicating that 1 in 8 women will develop the disease in their lifetime. Lumpectomy remains the predominant surgical intervention for treating... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.